Pfizer Inc. (NYSE:PFE) has earned a consensus recommendation of “Hold” from the twenty-one brokerages that are covering the company, MarketBeat.com reports. Fourteen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $46.47.
PFE has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Morgan Stanley set a $17.00 price objective on shares of BOX and gave the stock a “hold” rating in a research report on Tuesday, June 4th. Goldman Sachs Group upgraded shares of Solaredge Technologies from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $35.00 to $52.00 in a research report on Monday, June 17th. Credit Suisse Group set a $5.00 price objective on shares of Maxar Technologies and gave the stock a “sell” rating in a research report on Monday, July 15th. Finally, Bank of America initiated coverage on shares of Sogou in a research report on Monday, April 1st. They set an “underperform” rating and a $5.60 price objective for the company.
NYSE PFE traded down $0.29 during mid-day trading on Friday, reaching $42.77. 22,344,187 shares of the stock were exchanged, compared to its average volume of 21,624,544. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60. The business has a 50 day simple moving average of $43.09. The stock has a market cap of $237.80 billion, a P/E ratio of 14.26, a P/E/G ratio of 2.48 and a beta of 0.64. Pfizer has a 1 year low of $37.12 and a 1 year high of $46.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.10. The company had revenue of $13.12 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 earnings per share. Equities analysts forecast that Pfizer will post 2.88 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is 48.00%.
In related news, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the sale, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Home Federal Bank of Tennessee boosted its stake in Pfizer by 0.8% during the fourth quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock worth $1,297,000 after buying an additional 249 shares during the period. Congress Asset Management Co. MA boosted its stake in Pfizer by 2.0% during the fourth quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 254 shares during the period. D.B. Root & Company LLC boosted its stake in Pfizer by 0.7% during the fourth quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock worth $1,575,000 after buying an additional 255 shares during the period. Cottage Street Advisors LLC boosted its stake in Pfizer by 4.0% during the fourth quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 255 shares during the period. Finally, Advocacy Wealth Management Services LLC boosted its stake in Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 258 shares during the period. 71.87% of the stock is owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.